Perspective Therapeutics CATX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$111.13M-7.8% | -$103.12M+2.5% | -$105.8M-11.4% | -$94.95M-11.5% | -$85.17M-7.4% | ||
| $3.65M+12.1% | $3.25M+10.2% | $2.95M+3.7% | $2.84M+6.0% | $2.68M+16.3% | ||
| $9.42M+5.1% | $8.97M+2.9% | $8.72M+2.4% | $8.51M+24.7% | $6.83M+26.8% | ||
| —— | $0-100% | $24.1M— | —— | —— | ||
| -$20K+81.8% | -$110K+28.6% | -$154K— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $964K-52.1% | $2.01M-54.8% | $4.45M+0.2% | $4.44M+58.8% | $2.79M-22.4% | ||
| -$67K+89.4% | -$634K-194% | $677K-56.6% | $1.56M-1.2% | $1.58M-20.0% | ||
| $292K-11.8% | $331K-3.2% | $342K+20.4% | $284K+95.9% | $145K+164% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | $1.19M+1.6% | $1.17M+22.2% | $954K+8.4% | ||
| -$92.37M-12.0% | -$82.48M+2.3% | -$84.43M-30.3% | -$64.78M-20.6% | -$53.72M-194% | ||
| $14.95M+17.3% | $12.75M-42.8% | $22.29M-55.4% | $50.01M0.0% | $50M-8.1% | ||
| $247.57M+107% | $119.84M-54.6% | $264.01M+13.9% | $231.87M+23.7% | $187.38M+13.7% | ||
| $25.94M— | $0-100% | $198.4M+32.0% | $150.25M+49.6% | $100.43M+27.6% | ||
| —— | $0— | —— | —— | —— | ||
| -$62.76M-252% | $41.23M+133% | -$125.91M+25.8% | -$169.64M+4.3% | -$177.2M+19.1% | ||
| $54K+3.8% | $52K+2.0% | $51K-5.6% | $54K+10.2% | $49K+2.1% | ||
| $661K+78.2% | $371K-99.9% | $275.28M-0.2% | $275.7M0.0% | $275.68M0.0% | ||
| $164.71M+1,496% | $10.32M-3.2% | $10.66M-3.7% | $11.08M-91.7% | $133.03M-54.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | $1.19M+1.6% | $1.17M+22.2% | $954K+8.4% | ||
| —— | —— | —— | —— | —— | ||
| $964K-52.1% | $2.01M-54.8% | $4.45M+0.2% | $4.44M+58.8% | $2.79M-22.4% | ||
| $292K-11.8% | $331K-3.2% | $342K+20.4% | $284K+95.9% | $145K+164% | ||
| -$67K+89.4% | -$634K-194% | $677K-56.6% | $1.56M-1.2% | $1.58M-20.0% | ||
| —— | —— | —— | —— | —— | ||
| $126K-6.7% | $135K+2.3% | $132K+12.8% | $117K+44.4% | $81K+12.5% | ||
| $199.89M+14.9% | $173.95M+45.4% | $119.67M+67.3% | $71.52M+230% | $21.7M— | ||
| $54K+3.8% | $52K+2.0% | $51K-5.6% | $54K+10.2% | $49K+2.1% | ||
| —— | —— | —— | —— | —— | ||
| $1.46M+610% | $205K— | $0-100% | $618K-65.0% | $1.77M-16.5% | ||
| -$107.32M-12.7% | -$95.23M+10.8% | -$106.72M+7.0% | -$114.78M-10.7% | -$103.72M-42.7% | ||
| -$107.32M-12.7% | -$95.23M+10.8% | -$106.72M+7.0% | -$114.78M-10.7% | -$103.72M-42.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Perspective Therapeutics generate?
- Perspective Therapeutics (CATX) generated -$92.4M in operating cash flow over the trailing twelve months.
- What is Perspective Therapeutics's free cash flow?
- After $15.0M of capital expenditures, Perspective Therapeutics's free cash flow was -$107.3M over the trailing twelve months, down 3.5% year over year.
- Where does Perspective Therapeutics's cash flow data come from?
- Every line is extracted from Perspective Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
